TMO - Low Yield High Growth: Unveiling The Power Of Thermo Fisher's Dividends

2024-06-07 04:11:16 ET

Summary

• Thermo Fisher Scientific is well-positioned to benefit from the demand for innovation in the healthcare and biotech sectors.
• The company's strategic acquisitions have improved its growth capabilities and deepened its relationships with biopharma partners.
• Despite a low dividend yield, TMO has a history of strong total returns and consistent dividend growth, making it a compelling long-term investment.

Introduction

On April 24, I wrote an article covering Alexandria Real Estate Equities ( ARE ), a REIT that owns healthcare real estate, including laboratories.

This REIT is on my radar as a fantastic way to benefit from innovation in healthcare without having to figure out which biotech company will reveal a groundbreaking drug next....

For further details see: